Quest Diagnostics Q2 revenue up 10.2% to $3.04B; raises FY2026 guidance

QUEST DIAGNOSTICS INC

Q2 revenue $3.04B (+10.2% YoY), organic growth 10.0%.
Reported diluted EPS $2.84 (+15% YoY); adjusted diluted EPS $3.12 (+19.1% YoY).
FY2026 revenue guidance raised to $11.95B-$12.05B; adjusted EPS guidance raised to $11.05-$11.25.
Q2 cash from operations $597M, up 9.7% YoY.
Advanced Diagnostics growth (Alzheimer's, cardiometabolic); NY approval for Haystack MRD test.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.